European Medicines Agency recommends market authorisation for ocrelizumab (Ocrevus) in EU
The EMA has recommended that ocrelizumab (Ocrevus), the first disease-modifying treatment for primary progressive MS (PPMS), be prescribed for adults with early primary progressive MS